99mTc-HYNIC (Tyr3)-octreotide

Somatostatin Analog RadiopharmaceuticalRx: PrescriptionCompound: Investigational

Also known as: 99mTc-EDDA/HYNIC-TOC, 99mTc-HYNIC-(Tyr3)-octreotide, 99mTc-HYNIC-TOC, 99mTc‑HYNIC‑(Tyr3)‑octreotide, 99mTc‑HYNIC‑TOC, NeoTect, Tc-99m HYNIC-TOC, Tc-99m HYNIC‑TOC, Technetium-99m HYNIC‑Octreotide, Technetium‑99m labeled octreotide, Tektrotyd, TOC scintigraphy agent

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source 99mTc-HYNIC (Tyr3)-octreotide at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

99mTc-HYNIC‑(Tyr3)-octreotide is an investigational radiopharmaceutical that combines a somatostatin‑analogue peptide with technetium‑99m. After intravenous injection it binds somatostatin receptors on neuroendocrine tumour cells, allowing gamma‑camera imaging of receptor‑positive lesions. It is used primarily for diagnostic localisation, staging and follow‑up of neuroendocrine tumours, offering an alternative to the older 111In‑octreotide scans.

Mechanism of Action

The peptide octreotide analogue (Tyr3‑octreotide) retains high affinity for somatostatin receptors, especially subtype 2, expressed on many neuroendocrine tumours. The HYNIC chelator attaches technetium‑99m, a gamma‑emitter, to the peptide. Upon binding, the complex is internalised into tumour cells, while unbound tracer is cleared renally, creating a contrast that can be visualised with SPECT/CT.

What the Research Shows

Preclinical mouse models showed 99mTc‑HYNIC‑TOC achieving 5.8–9.6 %ID/g tumour uptake, comparable or superior to 111In‑octreotide, with rapid blood clearance and predominant renal excretion. Clinical series in adults reported overall sensitivity 95 %, specificity 92 % and accuracy 93 % for detecting neuroendocrine tumours, with especially high performance in foregut and midgut lesions. Patient‑specific dosimetry in 28 adults gave a mean effective dose of 4.6 ± 1.1 mSv and organ doses of 0.03–0.021 mGy/MBq; pediatric dosimetry indicated roughly 30 % higher organ doses. A separate analysis noted physiological uptake in the pancreatic uncinate process in about 19 % of scans, potentially mimicking malignancy.

Reported Benefits

The agent provides high tumour uptake and fast clearance, yielding clear images with good tumour‑to‑background ratios. Technetium‑99m is widely available and offers lower cost and easier logistics than indium‑111. Reported diagnostic performance is high for most neuroendocrine tumours, and patient‑specific dosimetry methods enable individualized radiation risk assessment.

Limitations of the Evidence

Detection accuracy is lower for hindgut neuroendocrine tumours. Physiological pancreatic uptake can lead to false‑positive interpretations. Organ and tumour radiation doses vary widely between patients, and pediatric dosing remains less well characterised. Evidence is limited to relatively small retrospective and single‑center studies; the compound remains investigational and is not yet approved for routine clinical use.

Safety Considerations

Radiation exposure is the primary safety consideration; the average effective dose is about 4.6 mSv per scan, with kidneys receiving the highest organ dose. Children receive approximately 30 % higher organ doses than adults. No acute adverse drug reactions were reported in the cited studies, but renal excretion warrants caution in patients with impaired kidney function. Standard radiation protection principles apply.

How It Is Administered

99mTc‑HYNIC‑TOC is administered intravenously, typically at activities around 740 MBq in clinical protocols. Imaging is performed 3–4 hours post‑injection using whole‑body planar scans and SPECT/CT to localise somatostatin‑receptor‑positive lesions. The tracer is cleared mainly via the kidneys.

Routes of Administration

Intravenous

Goals & Uses

  • Detection of meningiomasDiagnostic OncologyModerate
  • Staging and restaging of NETsDiagnostic OncologyHigh
  • Detection of neuroendocrine tumors (NETs)Diagnostic OncologyHigh
  • Staging of somatostatin‑receptor positive cancersDiagnosticModerate
  • Detection of small cell lung cancerDiagnostic OncologyModerate
  • SSTR2 expression assessmentDiagnosticModerate
  • Assessment of somatostatin receptor expression prior to PRRTTreatment PlanningModerate
  • Neuroendocrine tumor imagingDiagnosisModerate
  • Imaging of neuroendocrine tumorsDiagnosticModerate
  • Staging and localization of NETsDiagnosisHigh

Contraindications

  • Hypersensitivity to octreotide or somatostatin analoguesAllergyHigh
  • Known hypersensitivity to octreotide or excipientsImmunologicalModerate
  • Severe renal impairmentOrganModerateKidney function concerns
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Known hypersensitivity to octreotide or technetium‑99m compoundsAllergyHigh
  • Known hypersensitivity to octreotide or HYNICAllergyModerate
  • BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data

Adverse Effects

  • Radiation exposureRadiologicalCommon
  • Radiation exposure effectsRadiationCommon
  • Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
  • Hypersensitivity / anaphylaxisImmunologicalRare
  • Injection site reactionsLocalUncommon
  • Injection site painLocalCommonPain at the injection site
  • HypotensionCardiovascularRareLow blood pressure
  • Allergic reaction (urticaria, bronchospasm)ImmuneRare
  • FlushingVascularUncommonWarmth and redness of the skin
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Hypoglycemia or hyperglycemiaMetabolicRare
  • VomitingGastrointestinalRareForceful expulsion of stomach contents
  • Injection site reactionLocalUncommonRedness, swelling, itching, bruising, or pain at the injection site
  • Flushing or warmth sensationVascularCommon

Drug Interactions

  • GlucocorticoidsLow
  • Insulin and antidiabetic agentsLow
  • Other somatostatin analogues (e.g., lanreotide)Moderate
  • CorticosteroidsLow
  • Interferon-alphaLow
  • Long-acting somatostatin analogues (octreotide LAR, lanreotide)High
  • Long-acting somatostatin analogs (octreotide LAR, lanreotide)Moderate
  • Other radiopharmaceuticalsModerate

Population Constraints

  • Renal impairmentOrgan ImpairmentRelative
  • Patients on long-acting somatostatin analoguesPharmacologicalRelative
  • Pediatric patientsAgeRelative
  • Breastfeeding womenReproductiveRelative
  • Pregnant womenReproductiveRelative
  • Patients with severe renal impairmentOrgan ImpairmentRelative
  • Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

  • European UnionApprovedApproved: diagnostic imaging of somatostatin receptor positive tumorsMarketed under various trade names in EU member states.
  • United StatesInvestigationalNot FDA‑approved; used in clinical trials.
  • United KingdomUnknownNo specific MHRA approval identified post-Brexit; Ga-68–labeled agents are preferred in UK clinical practice.

Approved for diagnostic imaging in several EU member states; not FDA‑approved in the United States (investigational).

Evidence & Sources

Frequently Asked Questions

What type of tumours can be visualised with 99mTc‑HYNIC‑TOC?

The tracer binds to somatostatin receptors, most commonly over‑expressed on neuroendocrine tumours of foregut and midgut origin. It is less sensitive for hindgut lesions, which may show lower detection rates.

How does the radiation dose compare to other nuclear imaging agents?

The mean effective dose is about 4.6 mSv per study, comparable to many diagnostic nuclear scans. Organ doses are highest in the kidneys, and pediatric patients receive roughly 30 % higher doses than adults.

Can the scan give false‑positive results?

Yes. Physiological uptake in the pancreatic uncinate process occurs in about one‑fifth of patients without tumour, potentially mimicking a neuroendocrine tumour on SPECT/CT.

Is 99mTc‑HYNIC‑TOC approved for clinical use?

The compound is classified as investigational and is not yet approved as a routine diagnostic agent; it is used in research settings and limited clinical protocols.

What are the practical steps for performing the scan?

After an intravenous injection of the tracer, patients are imaged 3–4 hours later with whole‑body planar views and SPECT/CT. The images are interpreted for focal uptake corresponding to somatostatin‑receptor‑positive lesions.

What is 99mTc-HYNIC (Tyr3)-octreotide?

99mTc-HYNIC‑(Tyr3)-octreotide is an investigational radiopharmaceutical that combines a somatostatin‑analogue peptide with technetium‑99m. After intravenous injection it binds somatostatin receptors on neuroendocrine tumour cells, allowing gamma‑camera imaging of receptor‑positive lesions. It is used primarily for diagnostic localisation, staging and follow‑up of neuroendocrine tumours, offering an alternative to the older 111In‑octreotide scans.

What is 99mTc-HYNIC (Tyr3)-octreotide used for?

99mTc-HYNIC (Tyr3)-octreotide is educationally associated with: Detection of meningiomas, Staging and restaging of NETs, Detection of neuroendocrine tumors (NETs), Staging of somatostatin‑receptor positive cancers, Detection of small cell lung cancer, SSTR2 expression assessment, Assessment of somatostatin receptor expression prior to PRRT, Neuroendocrine tumor imaging, Imaging of neuroendocrine tumors, Staging and localization of NETs. Educational only — not medical advice.

How is 99mTc-HYNIC (Tyr3)-octreotide administered?

Recorded routes of administration: Intravenous.

What are the potential side effects of 99mTc-HYNIC (Tyr3)-octreotide?

Reported adverse effects include: Radiation exposure, Radiation exposure effects, Allergic reaction, Hypersensitivity / anaphylaxis, Injection site reactions, Injection site pain, Hypotension, Allergic reaction (urticaria, bronchospasm), Flushing, Nausea, Hypoglycemia or hyperglycemia, Vomiting, Injection site reaction, Flushing or warmth sensation. This list is not exhaustive — consult a qualified clinician.

Who should avoid 99mTc-HYNIC (Tyr3)-octreotide?

Recorded contraindications: Hypersensitivity to octreotide or somatostatin analogues, Known hypersensitivity to octreotide or excipients, Severe renal impairment, Pregnancy, Known hypersensitivity to octreotide or technetium‑99m compounds, Known hypersensitivity to octreotide or HYNIC, Breastfeeding. Consult a qualified clinician before use.

More Somatostatin Analogues

See all Somatostatin Analogues →

Browse All PeptidesBuild My Stack